Should Big Pharma Redirect Resources From Early R&D?
Executive Summary
With pharma under pressure from patent expirations and lack of innovative new products, research productivity is a hot button issue. Large drug companies increasingly rely on external sources to fill pipelines, but some industry observers say they're not going far enough.